GHRP-6: Hunger Signaling and Growth Hormone Research
A review of GHRP-6 (Growth Hormone Releasing Peptide-6), the first synthetic GHS compound studied in humans, covering its mechanisms, the hunger side effect profile, and what the published research shows.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It was one of the earliest synthetic growth hormone secretagogues to be studied in humans and holds historical significance as the compound that led to the identification of the GHS-R receptor.
The "6" in GHRP-6 refers to the number of amino acids; the compound belongs to a series that also includes GHRP-2 (a shorter, more potent variant) and GHRP-1 (the original in the series, now rarely studied).
Historical Context
The story of GHRPs begins with the observation by Cyril Bowers and colleagues in the 1970s and 1980s that certain enkephalin analogs appeared to stimulate GH release through a mechanism distinct from GHRH. Systematic medicinal chemistry work produced the GHRP series, and GHRP-6 was among the first to be administered to humans in research settings during the 1980s and early 1990s.
A key finding from this era was that GHRP-6 appeared to act on a receptor that was not GHRH-R. This unknown receptor was designated GHS-R and was eventually found to be the receptor for ghrelin — a hormone that was not identified until 1999. GHRP-6 thus served as a pharmacological tool that helped delineate a novel receptor system before its endogenous ligand was known.
Mechanisms: GHS-R and Beyond
GHRP-6 is an agonist at the GHS-R1a receptor. At the pituitary level, this may stimulate GH release directly; at the hypothalamic level, it may promote GHRH release and suppress somatostatin tone. The combination of these potential effects may amplify GH pulsatility.
However, GHRP-6 is less receptor-selective than later compounds like ipamorelin. Studies in humans have reported that GHRP-6 administration stimulates not only GH release but also:
- Cortisol and ACTH: Seen in both animal and human studies at research doses, suggesting activation of adrenocortical signaling pathways
- Prolactin: Elevations have been reported in some human studies
- Ghrelin-like appetite effects: The most distinctive off-target observation
The Hunger Side Effect
The most frequently reported subjective effect in humans administered GHRP-6 in research settings is a pronounced increase in appetite — colloquially described as an intense hunger sensation occurring within 15–30 minutes of injection. This is consistent with ghrelin's well-established role as an appetite-stimulating hormone.
The ghrelin system evolved primarily as a meal-initiation signal — ghrelin rises before meals and falls after eating. GHRP-6's activity at GHS-R in peripheral tissues (gut, hypothalamus) may reproduce aspects of this appetite signaling.
This hunger effect is a useful example of why receptor selectivity matters in compound characterization: the same receptor activation that may stimulate GH release at the pituitary also activates ghrelin-like appetite pathways. Later GHSs were developed specifically to reduce this overlap.
Published Human Research
Several published human studies from the 1980s–2000s examined GHRP-6's effects on GH secretion. These studies consistently reported dose-dependent increases in serum GH following IV or SC administration. Some studies examined combined GHRH + GHRP-6 administration and found synergistic GH increases, which supported the hypothesis that the two compounds work through complementary pathways.
The published human data on GHRP-6 is primarily pharmacodynamic (measuring GH levels) rather than clinical efficacy data. Long-term outcomes studies in human subjects are not available.
Comparison with Other GHSPs
| Compound | Selectivity | Appetite Effect | Cortisol Effect | Half-life |
|---|---|---|---|---|
| GHRP-6 | Lower | Pronounced | Moderate | ~15–20 min |
| GHRP-2 | Moderate | Less than GHRP-6 | More than ipamorelin | ~30 min |
| Ipamorelin | Higher | Minimal | Minimal | ~2 hours |
| Hexarelin | Lower | Moderate | More pronounced | ~30 min |
This comparison illustrates the receptor selectivity improvements made in successive compound development.
Research Utility
GHRP-6's value in contemporary research is partly historical and partly as a reference compound for studying the GHS-R system. Its less selective profile makes it a useful tool for delineating receptor-specific vs. non-specific effects when compared to more selective GHSs in the same experimental model.
For researchers specifically interested in GH release studies without appetite confounds, more selective compounds have largely replaced GHRP-6 as the primary research tool.
References
- 1.Bowers CY, Momany FA, Reynolds GA, Hong A. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology. 1984;114(5):1537-1545 [PubMed]
- 2.Popovic V, Leal A, Micic D, Koppeschaar HP, Torres E, Paramo C, Obradovic S, Dieguez C, Casanueva FF. “GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.” Lancet. 2000;356(9236):1137-1142. doi:10.1016/S0140-6736(00)02745-0 [PubMed]
- 3.Arvat E, Maccario M, Di Vito L, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. “Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.” Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1169-1174. doi:10.1210/jcem.86.3.7293 [PubMed]